| dbo:abstract
|
- Aganirsen (previously GS-101) is a 25 mer DNA antisense oligonucleotide therapeutic inhibiting insulin receptor substrate-1 (IRS-1), which is being investigated as a topical treatment for ocular neovascularization. Aganirsen is a candidate for the treatment of ocular neovascularization in patients with front of the eye (cornea) or back of the eye (retinal) diseases, including progressive corneal neovascularization in patients with infectious keratitis and wet age related macular degeneration (AMD). Aganirsen actively inhibits the production of IRS-1 by binding IRS-1 mRNA (antisense therapy). Aganirsen therefore induces an upstream inhibition of the neovascularization pathway, most notably by inhibiting excess VEGF and Il-1β expression. (en)
|
| dbo:iupacName
|
- all-P-ambo-thymidylyl-(3′→5′)-2′-deoxy-P-thioadenylyl-(3′→5′)-P- thiothymidylyl-(3′→5′)-2′-deoxy-P-thiocytidylyl-(3′→5′)-2′-deoxy-P- thiocytidylyl-(3′→5′)-2′-deoxy-P-thioguanylyl-(3′→5′)-2′-deoxy-P- thioguanylyl-(3′→5′)-2′-deoxy-P-thioadenylyl-(3′→5′)-2′-deoxy-P- thioguanylyl-(3′→5′)-2′-deoxy-P-thioguanylyl-(3′→5′)-2′-deoxy-P- thioguanylyl-(3′→5′)-2′-deoxy-P-thiocytidylyl-(3′→5′)-P- thiothymidylyl-(3′→5′)-2′-deoxy-P-thiocytidylyl-(3′→5′)-2′-deoxy-P- thioguanylyl-(3′→5′)-2′-deoxy-P-thiocytidylyl-(3′→5′)-2′-deoxy-P- thiocytidylyl-(3′→5′)-2′-deoxy-P-thioadenylyl-(3′→5′)-P- thiothymidylyl-(3′→5′)-2′-deoxy-P-thioguanylyl-(3′→5′)-2′-deoxy-P- thiocytidylyl-(3′→5′)-P-thiothymidylyl-(3′→5′)-2′-deoxy-P- thioguanylyl-(3′→5′)-2′-deoxy-P-thiocytidylyl-(3′→5′)-P-thiothymidine (en)
|
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 12906 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:imagesize
| |
| dbp:iupacname
|
- all-P-ambo-thymidylyl--2′-deoxy-P-thioadenylyl--P- thiothymidylyl--2′-deoxy-P-thiocytidylyl--2′-deoxy-P- thiocytidylyl--2′-deoxy-P-thioguanylyl--2′-deoxy-P- thioguanylyl--2′-deoxy-P-thioadenylyl--2′-deoxy-P- thioguanylyl--2′-deoxy-P-thioguanylyl--2′-deoxy-P- thioguanylyl--2′-deoxy-P-thiocytidylyl--P- thiothymidylyl--2′-deoxy-P-thiocytidylyl--2′-deoxy-P- thioguanylyl--2′-deoxy-P-thiocytidylyl--2′-deoxy-P- thiocytidylyl--2′-deoxy-P-thioadenylyl--P- thiothymidylyl--2′-deoxy-P-thioguanylyl--2′-deoxy-P- thiocytidylyl--P-thiothymidylyl--2′-deoxy-P- thioguanylyl--2′-deoxy-P-thiocytidylyl--P-thiothymidine (en)
|
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Aganirsen (previously GS-101) is a 25 mer DNA antisense oligonucleotide therapeutic inhibiting insulin receptor substrate-1 (IRS-1), which is being investigated as a topical treatment for ocular neovascularization. Aganirsen is a candidate for the treatment of ocular neovascularization in patients with front of the eye (cornea) or back of the eye (retinal) diseases, including progressive corneal neovascularization in patients with infectious keratitis and wet age related macular degeneration (AMD). (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
